AstraZeneca PLC Release: Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site

WILMINGTON, Del., Dec. 11 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) posted briefing materials in advance of the December 15(th) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to discuss the supplemental New Drug Application (sNDA) filed by AstraZeneca (NYSE: AZN - News). The briefing materials can be found on the FDA web site.